Trigeminal Neuralgia (Tic Douloureux) - Pipeline Review, H2 2019

Published by Global Markets Direct on 11th November 2019 | Ref: 1463983 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Trigeminal Neuralgia (Tic Douloureux) - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Trigeminal Neuralgia (Tic Douloureux) - Pipeline Review, H2 2019, provides an overview of the Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System) pipeline landscape.

Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from face to brain. Symptoms include spontaneous attacks of pain or attacks triggered by things such as touching the face, chewing, speaking and brushing teeth, pain in areas supplied by the trigeminal nerve, including the cheek, jaw, teeth, gums, lips, or less often the eye and forehead.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Trigeminal Neuralgia (Tic Douloureux) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Trigeminal Neuralgia (Tic Douloureux) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0 and Preclinical stages are 4, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Trigeminal Neuralgia (Tic Douloureux) - Overview

Trigeminal Neuralgia (Tic Douloureux) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Trigeminal Neuralgia (Tic Douloureux) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Trigeminal Neuralgia (Tic Douloureux) - Companies Involved in Therapeutics Development

Amgen Inc

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

InMed Pharmaceuticals Inc

Merz Pharma GmbH & Co KgaA

OliPass Corporation

PixarBio Corp

Trigeminal Neuralgia (Tic Douloureux) - Drug Profiles

carbamazepine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erenumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GTX-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

incobotulinumtoxin A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INM-405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OLP-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rimegepant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-266 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vixotrigine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Trigeminal Neuralgia (Tic Douloureux) - Dormant Projects

Trigeminal Neuralgia (Tic Douloureux) - Product Development Milestones

Featured News & Press Releases

Jul 03, 2019: Biohaven starts enrolment in rimegepant’s trigeminal neuralgia trial

Feb 27, 2018: PixarBio Corporation Clarifies Pathways to FDA Approval for NR14 to Treat Trigeminal Neuralgia and Post-Surgical Pain

Sep 15, 2016: PixarBio CEO Frank Reynolds to Present NeuroRelease a Non-Addictive Morphine Replacement at the 2016 Aegis Capital Growth Conference in Las Vegas, NV on September 21, 2016

Jun 27, 2016: PixarBio Promotes David Kaplan to Chief Commercial Officer, as NeuroRelease a Morphine Strength Non Addictive Pain Treatment Remains on Track for 2018 Launch

Mar 30, 2016: PixarBio, the Developers of NeuroRelease A Revolutionary Morphine Strength, Non-Addictive Pain Treatment Appoints Glenn Reiser Vice President of External Affairs

Mar 03, 2016: PixarBio's Dr. Taunia Markvicka and Glenn Reiser to Discuss Breakthrough Data on Morphine Strength Non-Addictive Pain Treatment NeuroRelease at the 2016 Congress of Neurological Surgeons Spine Summit held in Orlando, FL March 17-18, 2016

Nov 30, 2015: PixarBio's Glenn Reiser to Present Data on NeuroRelease, a Breakthrough Non-opiate and Non-addictive Pain Platform, at the 2015 Life Sciences Summit in New York, NY

Oct 26, 2015: PixarBio Announces USFDA OPD Submission of NeuroRelease TN for Orphan Drug Designation for Trigeminal Neuralgia

Sep 23, 2014: Convergence Pharmaceuticals' Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy

Jun 16, 2014: Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study

Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802

Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study

Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802

Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1463983 | GMDHC11431IDB

Number of Pages

76

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Markets Direct
18-03-2019

$2,000 USD

Published by Global Markets Direct
14-08-2018

$2,000 USD

Published by Global Markets Direct
20-02-2018

$2,000 USD

Published by Global Markets Direct
16-08-2017

$2,000 USD

Published by Global Markets Direct
15-03-2017

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Trigeminal Neuralgia (Tic Douloureux) - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.